open access

Vol 90, No 3 (2019)
ORIGINAL PAPERS Obstetrics
Published online: 2019-03-29
Get Citation

Continuous subcutaneous insulin infusion reduces neonatal risk in pregnant women with type 1 diabetes mellitus

Urszula Mantaj, Pawel Gutaj, Katarzyna Ozegowska, Agnieszka Zawiejska, Katarzyna Wroblewska-Seniuk, Danuta Olejniczak, Ewa Wender-Ozegowska
DOI: 10.5603/GP.2019.0028
·
Pubmed: 30950005
·
Ginekol Pol 2019;90(3):154-160.

open access

Vol 90, No 3 (2019)
ORIGINAL PAPERS Obstetrics
Published online: 2019-03-29

Abstract

Objectives: An attempt was made to demonstrate the superiority of the treatment model using continuous subcutaneous insulin infusion (CSII) over multiple daily injections (MDI) of insulin in achieving a successful pregnancy outcome and good newborn’s condition in patients with type 1 diabetes. 

Material and methods: The study included 297 infants born to type 1 diabetic patients; 175 patients were treated with MDI and 122 with CSII. 

Maternal metabolic control during pregnancy, gestational weight gain, insulin requirements, pregnancy outcome and neonatal status were compared between MDI and CSII arm. 

The composite adverse neonatal outcome was diagnosed if at least one of the following was found: abnormal birth weight (LGA or SGA), congenital malformation, miscarriage, intrauterine fetal death, emergency CS due to fetal risk, iatrogenic prematurity, RDS, hypoglycemia, hyperbilirubinemia, and the postpartum pH in the umbilical artery ≤ 7.1. 

Results: The studied groups did not differ regarding gestational week at delivery, a proportion of births at full term, preterm births, miscarriages, or late pregnancy losses (intrauterine fetal death > 22 weeks). Newborns of mothers treated with CSII showed lower incidence of neonatal complications (composite adverse neonatal outcome) compared to those of mothers treated with MDI (60% vs 74%, respectively; p = 0.01). We did not find any association between the mode of treatment and composite adverse maternal outcome. 

Conclusions: The use of CSII in the treatment of pregnant women with type 1 diabetes was associated with reduced number of neonatal complications presented as neonatal composite outcome but had no influence on maternal outcome.

Abstract

Objectives: An attempt was made to demonstrate the superiority of the treatment model using continuous subcutaneous insulin infusion (CSII) over multiple daily injections (MDI) of insulin in achieving a successful pregnancy outcome and good newborn’s condition in patients with type 1 diabetes. 

Material and methods: The study included 297 infants born to type 1 diabetic patients; 175 patients were treated with MDI and 122 with CSII. 

Maternal metabolic control during pregnancy, gestational weight gain, insulin requirements, pregnancy outcome and neonatal status were compared between MDI and CSII arm. 

The composite adverse neonatal outcome was diagnosed if at least one of the following was found: abnormal birth weight (LGA or SGA), congenital malformation, miscarriage, intrauterine fetal death, emergency CS due to fetal risk, iatrogenic prematurity, RDS, hypoglycemia, hyperbilirubinemia, and the postpartum pH in the umbilical artery ≤ 7.1. 

Results: The studied groups did not differ regarding gestational week at delivery, a proportion of births at full term, preterm births, miscarriages, or late pregnancy losses (intrauterine fetal death > 22 weeks). Newborns of mothers treated with CSII showed lower incidence of neonatal complications (composite adverse neonatal outcome) compared to those of mothers treated with MDI (60% vs 74%, respectively; p = 0.01). We did not find any association between the mode of treatment and composite adverse maternal outcome. 

Conclusions: The use of CSII in the treatment of pregnant women with type 1 diabetes was associated with reduced number of neonatal complications presented as neonatal composite outcome but had no influence on maternal outcome.

Get Citation

Keywords

neonatal outcomes; pregestational diabetes mellitus; CSII; MDI

About this article
Title

Continuous subcutaneous insulin infusion reduces neonatal risk in pregnant women with type 1 diabetes mellitus

Journal

Ginekologia Polska

Issue

Vol 90, No 3 (2019)

Pages

154-160

Published online

2019-03-29

DOI

10.5603/GP.2019.0028

Pubmed

30950005

Bibliographic record

Ginekol Pol 2019;90(3):154-160.

Keywords

neonatal outcomes
pregestational diabetes mellitus
CSII
MDI

Authors

Urszula Mantaj
Pawel Gutaj
Katarzyna Ozegowska
Agnieszka Zawiejska
Katarzyna Wroblewska-Seniuk
Danuta Olejniczak
Ewa Wender-Ozegowska

References (34)
  1. Feig DS, Palda VA. Type 2 diabetes in pregnancy: a growing concern. Lancet. 2002; 359(9318): 1690–1692.
  2. Wender-Ożegowska E. Maternal diseases complicating the course of pregnancy, Ed. Bręborowicz G. In: Diabetes. In: Obstetrics. Volume 2. Maternal-fetal medicine. . PZWL Medical Publishing, Warsaw 2012: 425–451.
  3. Dunne F. Pregestational Diabetes Mellitus and Pregnancy. Trends in Endocrinology & Metabolism. 1999; 10(5): 179–182.
  4. Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. Diabetologia. 2000; 43(1): 79–82.
  5. Miodovnik M, Lavin JP, Knowles HC, et al. Spontaneous abortion among insulin-dependent diabetic women. Am J Obstet Gynecol. 1984; 150(4): 372–376.
  6. Confidential Enquiry into Maternal and Child Health: Pregnancy in Women with Type 1 and Type 2 Diabetes in 2002-2003 in England, Wales and Northern Ireland. CEMACH London 2005. https://stratog.rcog.org.uk/sites/default/files/Diabetes%20and%20other%20endocrinopathies/CEMACH_Pregnancy_type_1_2_diabetes.pdf.
  7. Czeszyńska MB. Newborn of a mother with diabetes – past, present, future. Pediatric Clinic. 2006; 76: 828–837.
  8. Manderson JG, Mullan B, Patterson CC, et al. Cardiovascular and metabolic abnormalities in the offspring of diabetic pregnancy. Diabetologia. 2002; 45(7): 991–996.
  9. Wroblewska-Seniuk K, Wender-Ozegowska E, Szczapa J. Long-term effects of diabetes during pregnancy on the offspring. Pediatr Diabetes. 2009; 10(7): 432–440.
  10. White P. Pregnancy complicating diabetes. The American Journal of Medicine. 1949; 7(5): 609–616.
  11. Clinical recommendations for management of diabetic patients, 2011. Practical Diabetology. 2011; 12(A): 1–46.
  12. Wilczyński J, Cypryk K, Cyranowicz B. Incidence of birth defects in neonates of mothers with insulin-dependent diabetes. In: Słomko Z. ed. Materials of the I Congress of the Polish Society of Perinatal Medicine. PAN, Poznań 1995: 175–178.
  13. Meissner I, Whisnant JP, Khandheria BK, et al. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clin Proc. 1999; 74(9): 862–869.
  14. Ferreira-González I, Permanyer-Miralda G, Busse JW, et al. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J Clin Epidemiol. 2007; 60(7): 651–7; discussion 658.
  15. Yogev Y, Ben-Haroush A, Chen R, et al. Diurnal glycemic profile in obese and normal weight nondiabetic pregnant women. Am J Obstet Gynecol. 2004; 191(3): 949–953.
  16. Colstrup M, Mathiesen ER, Damm P, et al. Pregnancy in women with type 1 diabetes: have the goals of St. Vincent declaration been met concerning foetal and neonatal complications? J Matern Fetal Neonatal Med. 2013; 26(17): 1682–1686.
  17. Wender-Ożegowska E. Factors affecting fetal development during pregnancy complicated with diabetes mellitus. Supplement: Clinical Perinatology and Gynecology. ed. Słomko Z. The Scientific Publishers, Poznań 2000.
  18. Wender-Ozegowska E, Zawiejska A, Ozegowska K, et al. Multiple daily injections of insulin versus continuous subcutaneous insulin infusion for pregnant women with type 1 diabetes. Aust N Z J Obstet Gynaecol. 2013; 53(2): 130–135.
  19. Saisho Y, Tanaka C, Tanaka K, et al. Relationships among different glycemic variability indices obtained by continuous glucose monitoring. Prim Care Diabetes. 2015; 9(4): 290–296.
  20. Lepercq J, Taupin P, Dubois-Laforgue D, et al. Heterogeneity of fetal growth in type 1 diabetic pregnancy. Diabetes Metab. 2011; 27(3): 339–344.
  21. Johnstone FD, Mao JH, Steel JM, et al. Factors affecting fetal weight distribution in women with type I diabetes. BJOG. 2000; 107(8): 1001–1006.
  22. Small M, Cameron A, Lunan CB, et al. Macrosomia in pregnancy complicated by insulin-dependent diabetes mellitus. Diabetes Care. 1987; 10(5): 594–599.
  23. Combs CA, Gunderson E, Kitzmiller JL, et al. Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care. 1992; 15(10): 1251–1257.
  24. Martínez-Abundis E, González-Ortiz M, Pascoe-González S. Serum leptin levels and the severity of preeclampsia. Arch Gynecol Obstet. 2000; 264(2): 71–73.
  25. Gonzalez-Gonzalez NL, Ramirez O, Mozas J, et al. Factors influencing pregnancy outcome in women with type 2 versus type 1 diabetes mellitus. Acta Obstet Gynecol Scand. 2008; 87(1): 43–49.
  26. Cypryk K, Kosiński M, Kamińska P, et al. Diabetes control and pregnancy outcomes in women with type 1 diabetes treated during pregnancy with continuous subcutaneous insulin infusion or multiple daily insulin injections. Polish Archives of Internal Medicine. 2008; 118(6): 229–344.
  27. Evers IM, de Valk HW, Mol BWJ, et al. Macrosomia despite good glycaemic control in Type I diabetic pregnancy; results of a nationwide study in The Netherlands. Diabetologia. 2002; 45(11): 1484–1489.
  28. Kernaghan D, Farrell T, Hammond P, et al. Fetal growth in women managed with insulin pump therapy compared to conventional insulin. Eur J Obstet Gynecol Reprod Biol. 2008; 137(1): 47–49.
  29. Giménez M, Conget I, Nicolau J, et al. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study. Acta Diabetol. 2007; 44(1): 34–37.
  30. Neff KJ, Forde R, Gavin C, et al. Pre-pregnancy care and pregnancy outcomes in type 1 diabetes mellitus: a comparison of continuous subcutaneous insulin infusion and multiple daily injection therapy. Ir J Med Sci. 2014; 183(3): 397–403.
  31. Bruttomesso D, Bonomo M, Costa S, et al. Italian Group for Continuous Subcutaneous Insulin Infusion in Pregnancy. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI). Diabetes Metab. 2011; 37(5): 426–431.
  32. Talaviya PA, Saboo BD, Joshi SR, et al. Pregnancy outcome and glycemic control in women with type 1 diabetes: a retrospective comparison between CSII and MDI treatment. Diabetes Metab Syndr. 2013; 7(2): 68–71.
  33. Kekäläinen P, Juuti M, Walle T, et al. Continuous Subcutaneous Insulin Infusion During Pregnancy in Women with Complicated Type 1 Diabetes Is Associated with Better Glycemic Control but Not with Improvement in Pregnancy Outcomes. Diabetes Technol Ther. 2016; 18(3): 144–150.
  34. Lapolla A, Dalfrà MG, Masin M, et al. Analysis of outcome of pregnancy in type 1 diabetics treated with insulin pump or conventional insulin therapy. Acta Diabetol. 2003; 40(3): 143–149.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl